Is it appropriate to use senolytic agents such as dasatinib plus quercetin or fisetin for age‑related conditions, and what are the recommended dosing regimens, efficacy evidence, and safety considerations?

Senolytics for Age-Related Conditions

Current Clinical Status

Senolytic agents including dasatinib plus quercetin and fisetin should NOT be used outside of clinical trials at this time, as there is insufficient evidence from adequately powered human studies to support their routine clinical use for age-related conditions. 1, 2

What Are Senolytics?

Senolytics are drugs designed to selectively eliminate senescent cells—cells that have stopped dividing but resist normal cell death and secrete inflammatory molecules (SASP) that damage surrounding tissues. 1 These agents work by temporarily disabling the anti-apoptotic pathways that allow senescent cells to survive, causing selective death of harmful senescent cells while sparing normal cells. 1

Evidence Base

Preclinical Data

• In animal models, senolytics have shown promise for over 40 conditions including frailty, cardiovascular disease, neuropsychiatric disorders, kidney disease, musculoskeletal conditions, lung disease, metabolic disorders, and complications of cancer treatment. 1
• Dasatinib combined with quercetin, and fisetin as monotherapy, are the only agents that meet rigorous criteria for senolytic activity according to modified Koch's postulates. 3

Early Human Studies

• Very limited pilot trials suggest senolytics may decrease senescent cell burden, reduce inflammation, and potentially improve frailty measures in humans. 1, 2
• One small trial in diabetic kidney disease patients showed reduced senescent cells in adipose tissue with dasatinib plus quercetin. 2
• Another small study in idiopathic pulmonary fibrosis patients showed possible improvement in physical function. 2

Ongoing Clinical Trials

Clinical trials are currently underway or beginning for: 1

• Type 2 diabetes
• Idiopathic pulmonary fibrosis
• Alzheimer's disease
• COVID-19
• Osteoarthritis
• Osteoporosis
• Eye diseases
• Bone marrow transplant complications
• Childhood cancer survivors

Proposed Dosing Regimens (Investigational Only)

Dasatinib Plus Quercetin

• Administered intermittently using a "hit-and-run" approach, as senescent cells take weeks to reaccumulate. 1
• Specific dosing protocols vary by clinical trial and condition being studied. 2

Fisetin

• Used as monotherapy in some trials. 2, 4
• Fisetin demonstrates selective senolytic activity in certain cell types (human umbilical vein endothelial cells) but not others (lung fibroblasts, preadipocytes). 4

Mechanism of Action

Dasatinib and Quercetin

• Quercetin is a redox-active flavonoid with strong prooxidant activities that are amplified by transition metals (copper and iron). 3
• Senescent cells accumulate high levels of copper and iron, making them particularly vulnerable to quercetin's oxidative damage. 3
• Fisetin has higher prooxidant effects than quercetin and demonstrates greater senolytic activity. 3

Cell-Type Specificity

• Different senolytic agents show selectivity for different senescent cell types, which may explain why combination therapy (dasatinib plus quercetin) targets a broader range of senescent cells than single agents. 4

Safety Considerations

Known Risks from Related Compounds

• Dasatinib is FDA-approved for chronic myeloid leukemia and carries significant hematologic toxicity risks including grade 3-4 neutropenia and thrombocytopenia. 5
• Dasatinib can cause pleural effusion (37% cumulative incidence at 5 years), particularly in older patients with cardiac disease, hypertension, or hypercholesterolemia. 5
• Dasatinib affects platelet function and may cause bleeding disproportionate to platelet count. 5
• Drug interactions: Dasatinib is a CYP3A4 substrate; concomitant use with CYP3A4 inhibitors (ketoconazole, erythromycin, ritonavir) increases toxicity risk and should be avoided. 5

Quercetin and Fisetin Safety

• These flavonoids have relatively low toxicity profiles in preclinical studies. 4
• However, systematic safety data in humans using senolytic dosing regimens are lacking. 1

Population-Specific Concerns

• Older adults may have increased vulnerability to adverse effects given age-related changes in drug metabolism and clearance. 5
• Patients with renal impairment require careful consideration, as dasatinib dosing may need adjustment. 5

Critical Knowledge Gaps

• No adequately powered randomized controlled trials have demonstrated clinical benefit in humans for any specific age-related condition. 1
• Optimal dosing regimens, treatment duration, and intermittent scheduling protocols remain undefined. 2
• Long-term safety data are completely absent. 1
• Patient selection criteria (who benefits most) are unknown. 2
• Biomarkers to monitor treatment response and guide therapy are not established. 2

Clinical Recommendation

Until results from ongoing clinical trials are available, senolytics should only be used within the context of IRB-approved clinical trials with appropriate informed consent, safety monitoring, and data collection. 1 The potential for harm from off-label use of dasatinib (a chemotherapy agent with significant toxicity) combined with unproven benefit makes empiric use outside trials inappropriate. 5

Patients inquiring about senolytics should be counseled about:

• The experimental nature of these therapies. 1
• The lack of proven clinical benefit in humans. 1
• Known toxicity risks, particularly with dasatinib. 5
• Availability of clinical trials through institutions participating in the Translational Geroscience Network. 2